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Human Immunodeficiency Virus (HIV) has been affecting people since it was first discovered in 
1986. This is as a result of the HIV virus being present in the patient bloodstream for the 
remainder of their normal life, as there is no cure that exists as of now. HIV, if left unmanaged 
would end up developing into Acquired Immune Deficiency Syndrome (AIDS), a syndrome that 
weakens a patient’s immune system and leaves them susceptible to other opportunistic 
infections. Antiretroviral therapy (ART) has been successfully used in managing the progression 
of the HIV virus in the human body. However, poor adherence attributable to ignorance, adverse 
drug effects, and age have derailed the attainment of viral load suppression amongst the HIV 
positive people. The progression of the virus is tracked by counting Cluster of Differentiation 4 
positive cells, and the amount of virus in the blood (viral load) every 6 months. This research 
introduces the use of multi-layer artificial neural networks with backpropagation to predict the 
HIV/AIDS viral load levels over a given period of time (in weeks). The Data-driven Modelling 
methodology was used in the development of the model. This methodology was ideal since the 
model relied solely on pre-existing data, and supports artificial neural networks. The model 
developed performed at an accuracy level of 93.76% and a mean square error of 0.0323. The 
results showed that the neural network can be used as a suitable algorithm for HIV/AIDS viral 
load level prediction. The learning rate used in the study was 0.005 and the momentum was 0.9. 
The iterations for the training, testing and validation varied. 
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Chapter 1 : Introduction 
1.1. Background 
Since the discovery of Human Immunodeficiency Virus (HIV) as a virus in 1986 no cure has 
been found. This is majorly attributed to the dynamic nature of the virus that keeps morphing 
into new forms after very short periods of time. In Kenya, the first case of Human 
Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS) infection 
occurred in 1978, in communities living around the shores of Lake Victoria. It was later   
declared a National disaster November 1999 by the then president. Then National Aids Control 
Council (NACC) was established to coordinate all Aids programs in the country (National AIDS 
and STI Control Programme, 2014). 
HIV is a virus which leads to acquired immunodeficiency virus (AIDS), which causes failure of 
the immune system thus allowing other infections and cancers to affect the body and thrive 
(Chou, Iu, Krishna, & Liang, 2012). The virus is a retrovirus that attacks the human Cluster of 
Differential 4 (CD4+) cells, causing a decline in their natural defenses against pathogenic 
microorganisms (Rosa, Santos, Brito, & Guimaraes, 2014). It belongs to the Retroviridae family 
which is considered as a highly evolved virus type, and which can replicate in the host cells 
through Reverse Transcription process (Levy, 2007). 
Archer (2008) states that there are two major phenotypes of the HIV virus, namely HIV-1 and 
HIV-2. HIV -1, which this study will focus on has three strains; labelled as M (Major), O 
(Outlier) and N (New i.e. not M or O). He also states that the strain that is almost entirely to 
blame for the global pandemic is the Group M, which has a lot of diversity. HIV-2 is relatively 
uncommon and is concentrated majorly in the West of Africa. This phenotype is less infectious 
and progresses slower as compared to HIV -1 (Averting HIV and AIDS, 2016). HIV in this 
study, will refer to the more common HIV -1 phenotype.  
The majority of the infected people within Kenya are aged between 15-39 years which is a 
reflection of a population that has over 50% of its people being less than 16 years of age. The 
prevalence rate of HIV amongst this group is 5.9%. The major factor contributing to the high 
incidence of HIV/AIDS in Kenya has been attributed to the high level of poverty among 
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Kenyans where over 50 percent of the population lives with an average annual basic income of 
less than $1 per day (National AIDS and STI Control Programme, 2014;UNAIDS, 2017).  
Consequentially, a lot of research has gone into trying to come up with a solution to HIV/AIDS 
with the recent temporal solution being the invention of the Antiretroviral Therapy (ART) drugs, 
composed of a compound of medicines aimed at slowing down the rate at which the HIV virus 
replicates itself. However, a bigger quartile of the population of the third world countries is still 
suffering from logistical challenges such as lack of adequate medical equipment and medical 
supplies in the hospitals, and the high prices of undertaking the activities and tests. Worst case 
scenarios have included the introduction of ART in the late stages of a HIV patients (Lopez, 
2011).   
 In the recent decades the use of data relating to HIV protein levels in the plasma, also known as 
clinical markers have been used to estimate prognosis in HIV-1 infection. In as much as it has 
been affirmed that the best predictor of AIDS onset characterized to date is the percentage or 
absolute number of circulating (Cluster of Differentiation 4 positive) CD4+ T cells, a marker or 
combination of the same have recently been used to assess risk before substantial immune 
destruction kicks in (United Nation AIDS, 2016). The CD4+ count is a measure of the number of 
white blood cells per milliliter of blood that contain the CD4 glycoproteins. The CD4+ cells are 
usually developed in response to infections (Chou, et al., 2012). Viral load on the other end, is a 
measure of the actual number of viral particles per milliliter of blood. This count is more 
accurate than the CD4+ count since CD4+ cells are usually detected after the drug resistance has 
been developed, and can also be affected by other factors other than HIV infection, such as other 
infection (HIV Viral Load Blog, 2016; Chou, et al., 2012). 
Other than just research, a lot of resources have gone into sponsoring activities to predict an 
improvement in a patient's viral load. This in most instances has normally entailed the 
participating competitors being provided with data on the nucleotide sequences of the Reverse 
Transcriptase (RT), the Protease (PR), the viral load and the CD4 count of different cases that 
suffer from HIV as at the beginning of therapy. The variables provided in these competitions 
have proven to be reliable and highly co-relational to the levels of HIV within a patient’s body. 
The predictions output are normally then tested against a number of real cases. These exercises 
have over the time contributed to the use of data guided by the aforementioned parameters 
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amongst others to better place the status of the HIV patients (Shafer, Dupnik, Winters, & 
Eshleman, 2001).  
1.2. Problem Statement 
ART medicine dispensation has for some time been used as a combative mechanism to slow the 
quick spread of HIV virus within the infected persons. In addition to this, viral load tests are 
normally carried out as an important exercise to aid the medical practitioners know how much 
the virus has spread in the body for purposes of monitoring the levels or kinds of ART to 
administer to the infected persons. This is because, as the viral load increases, the response to the 
medicines administered also gets altered and in most cases thus needs to be changed; with fewer 
cases of adherence to the original prescribed drug. Failure to this leads to unresponsiveness to the 
ART and thus puts the patients at a graver risk (Institut National de Sante' Publique du Quebec, 
2014).  
At the moment, especially within Kenya, patients are advised to visit the hospital at least twice a 
year for viral load tests which are conducted clinically through the use of various clinical 
markers within the hospitals’ laboratories. This approach is so far not effective due two major 
reasons. First, most patients, as dictated by their lifestyle are not committed to keeping these 
yearly appointments and thus with time end not responding to the prescribed ART. Such lifestyle 
range from poor eating habits to alcoholism (Nyaga, et al., 2004). The other major factor that 
makes this approach ineffective is the limited resources required to conduct these activities 
within the hospitals in relation to the large population of HIV infected patients. There are CD4 
prediction systems that are currently existing. However, the CD4 prediction comes later after the 
viral load of a given patient is far much overwhelming and thus no longer useful in preventing 
the quick spread of the HIV virus. 
1.3. Aim  
The aim of this research is to develop a prediction system for determining viral load levels at 




1.4. Research Objectives 
i. To investigate the factors influencing HIV/AIDS progression in human beings 
ii. To analyze the methods used for the measurement of HIV/AIDS progression 
iii. To review the existing prediction algorithms and models used in prediction of HIV/AIDS 
progression 
iv. To develop an HIV/AIDS Viral load prediction system 
v. To test the functionality of the developed HIV/AIDS Viral load prediction system 
1.5. Research Questions 
i. What are the factors influencing the progression of HIV/AIDS amongst HIV positive 
patients? 
ii. How is the HIV/AIDS progression measured? 
iii. What are the prediction algorithms and models currently being used to predict 
HIV/AIDS? 
iv. How can the HIV/AIDS viral load prediction system be developed, and what 
methodology or framework will used in the implementation? 
v. How can the functionality of the developed system be tested? 
1.6. Justification 
Albu and Stanciu (2015) highlight the benefits of using artificial intelligence in the medical field. 
Simplifying the physician’s work, saving their time and energy, detecting imperceptible things 
that would have otherwise been missed are some of the benefits that they state. They conjecture 
that through the use of artificial intelligence, we can be able to have more insight into hidden 
attributes, especially when using a prediction system.  
Winters-Miner (2014) also notes that the use of predictive analytics in medicine can lead to 
improved diagnosis. The doctors will be harnessing the power of models created over a period of 
time to augment their skill in patient-care. This would ultimately lead to better outcomes for the 
patient. The predictions can lead to the use of preventive medicine where the patient’s lifestyle is 
changed to prevent health risks in future. Stayerberg (2009) agrees with the assertion on better 
outcomes for the patient and conjectures that this prediction ability can help weigh the benefits 
of risk of medicinal side-effects with the rewards, and therefore better medical decisions made. 
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Therefore prediction systems can be used in medicine to improve patient-care together with 
doctors’ skills and input.  
Lopez (2011) states that the People Living with Human Immunodeficiency Virus and Acquired 
Immune Deficiency Syndrome (PLWHA) can lead normal lives, even after the initial diagnosis 
with the HIV virus. The author stipulates that the management of HIV/AIDS has been successful 
through the use of ART, which prolongs the lives of the PLWHA. These ART regimens are 
provided based on the viral load of the HIV virus in the blood of the patient (Medecins sans 
Frontieres, 2010). 
1.7. Scope and Limitation 
The scope of this research was limited to the use of online data to develop the HIV/AIDS viral 
load prediction system. Due to the sensitivity of the data under consideration, getting the data 
from local hospitals in Kenya is very challenging as most are very protective. For this reason, the 
study would utilize anonymized patient data that is publicly available online.  The data obtained 
does not contain any adherence information, so this research is limited to the attributes available, 




Chapter 2 : Literature Review 
2.1. Introduction 
In this chapter, we look at the working of the HIV virus in the human body, and how the 
antiretroviral medication has been used to manage the virus. We also look at the ways in which 
the HIV virus has been observed to have formed resistance against the available antiretroviral 
medication. Finally, we evaluate the existing systems that have been used to try and predict the 
viral load levels in an HIV positive patient and highlight the shortcomings of the research.  
2.2. Factors influencing HIV/AIDS Progression 
2.2.1. How HIV Infects the Body 
Infection of HIV occurs when the HIV pathogen comes in direct contact with the blood of a HIV 
– negative person. This can occur during unprotected sexual contact with an HIV positive 
person, sharing of sharp objects such as syringes with an HIV positive person, or an HIV- 
negative person with an open wound coming into contact with contaminated blood such that their 
blood mixes with the contaminated blood.  
The major means of transmission of HIV is contaminated blood products, sexual contact- 
homosexual contact being higher than heterosexual contact, and mother to child transmission. It 
is impossible to detect HIV through the symptoms that are displayed as they largely mimic other 
infections and diseases. Thus the only definitive way of knowing if one is infected with HIV is 
through testing of blood or saliva (Cohen, 2007; Levy, 2007).  
The HIV tests that are submitted for adults look for the antibodies that are present in the blood. 
These antibodies are produced in response to the presence of the HIV virus in the blood. In 
adults, a rapid test can be used to test. The efficiency rate of the tests varies depending on the 
time since the exposure of the person to the HIV virus. During the first three months, there is a 
very high level of viral replication, and thus the antibodies may not be detectable. Modern rapid 
tests, however, have a higher efficiency rate and are able to detect the presence of the virus 
within two weeks of possible exposure (Miller, et al., 2002). 
Once the virus has entered the bloodstream, they begin the process of replication. The virus 
attacks the white blood cells of a body, also called T-helper cells or CD4+ cells. These CD4+ are 
important since they help in fighting off diseases and infection in the human body. Given that the 
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HIV virus does not have the ability to multiply, they replicate within the CD4+ cells through 
reverse transcription process. This results in the damage of the immune system and thus weakens 
the body’s natural defense system (Averting HIV and AIDS, 2016). Figure 2.1 shows how the 
HIV virus infects the CD4+ cells.  
 
Figure 2.1: HIV virus infects the CD4+ cell (Adapted from Averting HIV and AIDS (2016)) 
The HIV virus infects the CD4+ cell and the two Ribonucleic Acid (RNA) strands which are 
synthesized to  HIV Deoxyribonucleic Acid (DNA) through the enzyme reverse transcriptase. 
This process is referred to as the reverse transcription (Averting HIV and AIDS, 2016). 
During the reverse transcription process, the reverse transcriptase enzyme converts the RNA 
template into DNA. This is done and the newly synthesized DNA is integrated into the cell DNA 
through the use of the integrase protein. This is what determines the lifelong nature of HIV 
infection. A new HIV virus is then assembled within the cell and exits the cell while not yet fully 
mature. It takes some essential proteins as it leaves the cell, and matures outside the infected cell. 
The mature cell is then able to infect other CD4+ cells (Fevrier, et al., 2011; AIDS Gov, 2016).  
The available antiretroviral regimens in use target the HIV virus during the initial fusion of the 
HIV cell, the integration of the HIV DNA into the cell DNA and the convention of the HIV RNA 
to DNA. This is done by introducing blockers that prevent the execution of the same processes. 
In the initial fusion, a blocker to prevent the HIV virus from fusing with the CD4+ cells prevents 
the introduction of the HIV RNA into the cell. Some antiretroviral medication introduce blockers 
to prevent the integration of the HIV DNA into the cell DNA. This thus prevents the lifelong 
infection of HIV (myMVC, 2016).  
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2.2.2. Antiretroviral Therapy Adherence 
Antiretroviral adherence is the strict following of the prescribed antiretroviral medication 
regimen, by an HIV positive patient. AIDS INFO (2016) states that strict adherence to the 
antiretroviral therapy is key to sustained HIV suppression, reducing the drug resistance and 
improving the quality of life, overall health and survival. This is important because lack of 
adherence to the medication could lead to the patient losing all future treatment options as a 
result of the drug resistance. However, adherence to therapy is difficult to measure. Chesney 
(2000) identifies four basic techniques that have been developed to quantify adherence. These 
techniques are having the patient self-report, patients’ reports of missing pills, assays of drug 
levels, and electronic monitoring systems.  These methods have their challenges. In the self-
reporting method, the challenge is that the patient may inflate their adherence. This method will 
also only work in the short term.  
Chesney (2000) points out that the challenge to the patients’ reporting the missing pills is the 
discarding of the medication packaging and pill-dumping. This method requires that the patient 
brings back the remaining pills and the original medication package, which they may have 
discarded. Some patients will also discard some pills so that they appear to be adhering to the 
regimen. Nonetheless, this method is said to be almosy always reliable. Drug assays are 
expesinve, and can be misleading if a patient who is aware takes medication before visiting the 
clinic. Electronic monitoring systems on the other hand, assume that single doses are taken 
whenever the pill bottle is opened. This is misleading especially if multiple doses are removed at 
once.  
Several studies, Wasti, et al., (2012); Beer, et al., (2012), report that a high level of adherance to 
ART is necessary to maintain viral suppression and maintain optimal clinical outcomes for HIV-
positive persons. One study, Wasti, et al., (2012) , goes further and identifies that an adherance 







2.2.2.1. Factors Affecting ART Adherence 
Studies have revealed various reasons for nonadherance, ranging from social to side effects of 
medication. Perception about ART, religion and rituals, alcohol intake, lack of family support, 
economic issues, distance, stigma and discrimination, short period of medicine prescription, 
gender and insufficent pills in the packeaged bottles were some of the reasons identified . It is 
important to note that in that particular study, gender was identified given the socio-cultural and 
economic limitations that Nepal has placed on the people of the female gender. The short period 
in which medcine is prescribed, in this case, either one or two months is influenced by the 
financial aspect of medication.  
This therefore means that should a person be located far away from a dispensing area, then they 
might miss getting refills. Age (younger age) and binge drinking (related to alcohol abuse) were 
consistently found to have negatively affected adherence to ART regimen. Chesney (2000) 
however cautions that some, and not all studies have shown an association between 
nonadherence and youth, female gender, low educational level, or a current or past history of 
substance abuse. 
2.2.2.2. Impact of ART resistance in HIV Positive Patients 
As seen in the studies above, there is a clear correlation between the social issues and the 
adherence levels among HIV-positive patients. This non-adherence has also been established to 
lead to higher viral loads amongst the patients as shown by (Beer, et al., 2012).This therefore, 
could lead to ART treatment resistance.  
ART treatment resistance can result in reduced survivability and increased mortality, cross-
resistance, and transmission of ART-resistant HIV strains. Bertagnolio et al., (2013) states that 
the survivability of the HIV-positive patient in the future would be reduced by 18% where the 
ART resistant strains are transmitted. This indicates a high mortality rate that can be purely 
attributed to the development of ART-resistance.  
AIDS INFO (2016) defines cross-resistance as the situation in which resistance to a HIV 
medicine causes resistance to drugs within the same HIV medicine’s class. This class refers to 
the group within which they fight HIV. This could lead to a person having resistance to a drug 
which they have never even interacted with before.  
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In mother-to-child transmission, the strain of the HIV virus that is resistant to the ART regimen 
can be passed to the unborn child. This means that they will in effect lose all future options in the 
use of the same line of ART regimen. In cases where there is cross-resistance, the unborn child 
could also lose the second line regimen if the drug is in the same class (Bertagnolio et al., 2013). 
2.2.3. HIV Superinfection and Coinfection 
Grant and McConnell (2017) define superinfection as the acquisition of multiple HIV strains 
from multiple partners, where one of the strains of the virus is obtained after seroconversion. 
Smith, Richman and Little (2005) expand this definition and define it as the infection by a 
second strain after the initial infection and immune response to it has already been established.  
Coinfection is where an HIV-positive patient acquires another/other strains of the HIV virus 
from multiple partners during the initial stages of infection i.e. before an immune response to the 
first strain has been established (Smith et al., 2005). The high amounts of viral load in the blood 
could possibly lead to superinfection with the HIV virus, although Grant & McConnell (2017) 
agree that more research as to this relation should be done.  
The assumption that once a person who has already been infected with the HIV virus cannot be 
reinfected leads to risky sexual behaviour amongst the HIV positive patients, which might lead 
to superinfection. In the reported cases of superinfection, there was reported increase in the viral 
load levels and decrease in the CD4+ cells, which is similar to that during the primary (initial) 




Table 2.1: Table showing published cases of HIV-1 superinfection (Adapted from (Smith, 
Richman, & Little, 2005) 
 
From the table above, it is clear that there was accelerated/increased disease progression after the 
superinfection. This disease progression can be measured by taking the CD4+ counts and/or the 
viral load. It was also clear that there was some drug resistance in some of the studies where 
there was superinfection.  
2.3. Methods for measuring HIV/AIDS Progression 
HIV/AIDS progression can be measured in two ways, by measuring the CD4+ count and the 
viral load levels in the human body. 
2.3.1. Viral Load 
(Government of Quebec, 2015; Miller, et al., 2002) define viral load as the amount of virus in an 
organism, given in terms of virus particles per milliliter. This viral load refers to the number of 
viral copies of the HIV RNA strands per milliliter (mL) of blood.  In HIV/AIDS management, 
this is usually a good indicator as to the immunity status of the body, and the efficacy of the ART 
regimen being used. Chou et al., (2012) affirms this by stating that this variable (viral load) is 
useful in the determination of whether a treatment is working on a patient for a given disease.  
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Wilson, et al. (2008) assert that the people with HIV infection receiving effective antiretroviral 
therapy i.e. those with undetectable plasma HIV viraemia (that is <40 copies of HIV RNA per 
mL), who do not have other genital infections cannot transmit HIV through sexual contact. 
Figure 2.2 shows the relation between the probability of HIV transmission per sexual act, and the 
amount of viral copies in the blood. It shows an gradual increase in the transmission risk with an 
increase in the viral load. Should the assertion by Wilson et.al be proved as true, since at the time 
of the study, medical and biological data did not permit proof of that assertion, predicting the 
viral load could be instrumental in the attainment of the 90-90-90 treatment objective.  
The 90-90-90 treatment target sets the goal of, having 90% of PLWHA knowing their HIV 
status, 90% of people who know their HIV-positive status accessing treatment and 90% of 
people on treatment having suppressed viral loads by the year 2020 (United Nation AIDS, 2016; 
Levi, et al., 2016). The suppressed viral load in this case is having the undetectable viral load 
levels. This would also be helpful in preventing the spread of HIV amongst serodiscordant 
couples; where one partner is HIV positive and the other partner is HIV negative. It is however 
important to note that the absence of HIV transmission by HIV positive patients was observed in 
the studies where treatment adherence, absence of STBBIs, regular medical follow-up and 
counselling were met (Government of Quebec, 2015).  
 
Figure 2.2: Graph showing relation between Transmission Probability of HIV per Sexual Act and 





From the figure above, it is clear that the probability of HIV transmission is higher where there is 
a greater viral load. This highlights  the need to lower the viral load levels in order to attain one 
of the tenets of the 90-90-90 goal and prevent future occurrence of the virus. 
Viral load testing is also instrumental in determination of the necessity of a change in the ART 
regimen for a HIV positive patient. This aid in preventing unneccessary ART regimen changes 
and can encourage the patient to adhere to the ART regimen given (United Nation AIDS, 2016). 
Viral load is a more sensitive measure of HIV progression.  
2.3.2. Cluster of Differentiation 4 
The cluster of differentiation 4 (CD4+) is a glycoprotein found on the surface of the T-cells. The 
T-cells are a type of white blood cells. The CD4+ count is the count of the number of CD4+ cells 
per milliliter (mL) of blood. This count is used to estimate the number of white blood cells that 
are existing per milliliter of blood. The CD4+ cells are used as a conduit by HIV to bind itself to 
the T-cells, therefore can be used as an indicator of the HIV progression in a HIV positive 
patient. A higher CD4+ count denotes a healthier patient, but also denotes a high amount of HIV 
reproduction (Chou et al., 2012).  
Immunological markers such as CD4+ counts has been traditionally used in the diagnosis of 
treatment failure in HIV positive patients. The drawback in using CD4+ counts as a measure of 
treatment failure in HIV positive patients is that their detection comes after resistance to the drug 
has already been developed. This therefore necessitates switching of the regimen to a second-line 
or third-line regimen, which are more expensive (United Nation AIDS, 2016).  
2.4. Current HIV/AIDS Prediction Systems 
Here, we look at the various existing prediction systems and frameworks, analyzing their 
strengths and weaknesses. 
2.4.1. Prediction of HIV/AIDS Status using Artificial Neural Networks 
Artificial Neural Networks (ANNs) are processing devices, that are loosely modeled after the 
structure of the human brain. The structure is more like a miniature brain in that whereas the 
brain contains billions of neurons, a large ANN might have hundreds or thousands of processor 
units. ANNs are organized in layers that are made up of interconnected nodes containing an 
activation function. Information is provided to the network via the input layer, which 
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communicate to the hidden layer(s) where the actual processing is carried out. The processing is 
undertaken via a system of weighted connections which are linked to the output layer. The output 
layer is responsible for showing the answer (Chebet, et al., 2014) . Figure 2.3 shows the ANN. 
 
Figure 2.3: Structure of an Artificial Neural Network (Adapted from Chebet, et al., (2014)) 
2.4.1.1 Neuron 
Figure 2.4 shows the mathematical model for a neuron. A typical neuron consists of inputs and 
weights w0 to wi that will be fed into it. A bias weight is also included into the neuron. These 
inputs with the corresponding weights are then passed through the activation function to produce 
an output. This output can be used as an input to another neuron.  
 
 





2.4.1.2 Activation Function 
The activation function’s task in a neural network is to transform the input value to the output 
value in a neuron (Doorn, 2014). Every neuron in the network will require that the input is 
converted into a value between 0 and 1, and this is done by the use of activation functions. The 
sigmoid activation function is the most widely used activation function. Equation 2.1 shows the 
sigmoid function.   
Equation 2.1: Sigmoid Equation Used (Adapted from (Doorn, 2014)) 
 
The output of the sigmoid function is shown in Figure 2.5 below. The graph shows the values 
from zero to a maximum of one. The output, therefore, will fall in between the range 0-1. 
 
Figure 2.5: The Sigmoid Activation Function Graph (Adapted from (Doorn, 2014)) 
Emuoyibofarhe, et al., (2016) introduce a confirmatory test for determining the accurate 
diagnosis of HIV, by use of Artificial Neural Networks. They use the result of the Enzyme 
Linked Immuno Sorbent Assay (ELISA) test as inputs into the neural network. The ELISA test 
represents the standard for screening blood samples infected with HIV from none infected 
samples in Nigeria.  
However, the diagnosis from this test is still far from being standard in the Nigerian Health 
sector. Since the diagnosis is subject to human error. (Emuoyibofarhe, et al., 2016) successfully 
applied multi-layer Neural Networks to the prediction and hence diagnosis of HIV using the 
results of the ELISA tests. They used a feed forward back propagation network that was 
successfully trained with data of various HIV positive sample and HIV Negative samples and 
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upon completion of the training, new data were sought, interpreted, and supplied as input into the 
Network.  
The diagnosis of the network showed 94% prediction accuracy based on 9 epochs. 
(Emuoyibofarhe, et al., 2016)’s research successfully established the applicability of Artificial 
Neural network to the diagnosis of HIV based on the result of the ELISA test and it is expected 
that it will assist medical practitioners to give a more accurate diagnosis of HIV. 
2.4.2. Random Forest Algorithm 
Ali, Khan, Ahmed and Maqsood (2012) define random forests as a classifier combination 
utilizing the L tree-structured base classifiers {h(X,Ѳn), N=1,2,3,…L}, where X denotes the 
input data and {Ѳn} is a family of identical and dependent distributed random vectors. Each 
decision tree here, is made through the random selection of data, from the entire set of all 
available data. A random forest can be built through the random sampling of a feature subset, or 
the random sampling of the data subset used in training of each decision tree. This is also called 
bagging. (Liaw & Wiener, 2017) explains the concept of bagging as being the case where the 
succeeding decision trees do not rely on the earlier trees, but each of them is developed 
independently from a striped down sample of the data set.  
Random forest algorithm has been used in the prediction of the probability of the HIV positive 
patient’s viral load falling below 50 copies per ml following the change in therapy. In this study, 
(Revell, et al., 2012), the input variables used were baseline Viral Load, CD4 count, treatment 
history and the time to follow-up. This basically forms the Treatment Change Episode (TCE). 




Figure 2.6: Treatment Change Episode (Adapted from (Revell, et al., 2012)) 
The TCE captures the initial viral load level, CD4+ count and the genotype before the start of the 
new treatment. During the course of the new treatment, there will be periodic measurement of 
the viral load levels within a patient to see if the treatment is working. Revell, et al., (2012) used 
3188 TCEs and tested with 100 TCEs, and developed two models; one considering the genotype, 
and the other ignoring the genotype. In their study, they conjecture that the use of the genotype 
affected the performance of the prediction by a small factor, and that it was insignificant. Their 
model without genotype resulted in the area under the curve (AUC) for the 0.88 while that with 
genotype had an AUC result of 0.86. This result was lowered when the TCEs originating from 
Romania to 0.60. This shows that their model can be used in limited resource setting where the 
genotype information may not be readily available.  
Zoya and Sezerman, (2016), used random forests to test which structural and sequence features 
can be used to predict drug resistance amongst HIV positive patients with remarkable results. 
Their random forest classifier showed accuracy measures ranging between 98-99.2%. The study 
focusses more on the amino acid sequences of the HIV-1 Protease and Reverse transcriptase, and 
looked at the single and multiple mutations of HIV resistance, while inferring the interactions 
between them. The feature set considered included hydrophobicity measure, evolutionary 
conservation, flexibility measure, disordered proteins, and amino acid volume information, for 
the sequence features, whereas the structural features considered the 2D and 3D representation 
together with the contact energies.  
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2.4.3. Support Vector Machines 
Cai, Liu, Xu and Zhou (2001) define support vector machines as a kind of learning machine that 
is based on statistical learning theory. It works by first mapping the input vectors into one feature 
space, linearly or non-linearly, relevant to the selection of the kernel function. Then withing the 
feature space from the first step, a hyperplane separating the two classes (or multiclass) is 
constructed. Figure 2.7 shows an example of the classification using support vector machines. 
 
Figure 2.7: Support Vector Machines Example (Adapted from (Aylien, 2016)) 
Zoya and Sezerman, (2016) also developed a support vector machine classifier in their study. 
They used the same structural and sequence features in this case and obtained accuracy measures 
of 95-96%. The parameters used had to be tweaked in order for the study to achieve the highest 
possible accuracy. Due to the sensitivity of the classifier with regard to class imbalance, they 
applied sampling techniques to the dataset in order to prevent misclassification.  
2.4.4. Linear Regression 
Craenenbroek, et al., (2007) applied linear regression on an HIV-1 genotype and phenotype 
database to predict the resistance of HIV-1 phenotype from the viral genotype. In this study, the 
phenotypic measurement was estimated as the weighted sum of the effects of the individual 
mutations. The mutation pairs were included in order to account for the synergistic and 






Linear regression is used to study the linear relationships that exist between a dependent variable 
and one or more independent variables. The dependent variable is expected to be continuous 
while the independent variable could be continuous, binary or categorical in nature (Schneider, 
Hommel, & Blettner, 2010). In this method, the relationship between the dependent and 
independent variables under consideration must be linear.  
In cases where more than one independent variables linearly relate to giving the output of the 
dependent variable, then multivariable linear regression is used. The independent variable can 
then be defined as the linear function of the independent variables Xi. Equation 2.2 shows the 
liner regression formula. The dependent variable Ŷt is a function of the relation between the 
independent variables X1t and Xkt where k is the number of variables. β0 represents the intercept 
for the regression equation and β1 to βk represent the gradients for each of the independent 
variables.  
 
Equation 2.2: Linear Regression Formula (Adapted from  (Freyder, 2014)) 
 
Freyder (2014), states that some assumption have to be made in order to use linear regression. 
First, the effects of each of the independent variables on the dependent variable should be linear 
and additive. This means that they should each contribute to the dependent variable in an even 
manner. Secondly, the independent variables should be independent of each other. The 
independent variables should not rely on each other nor should they contribute to each other. 
They should all be contributing to the dependent variable in an equal manner. Thirdly, the errors 
contained in the model are normally distributed and the variance (homoscedasticity) for the 
errors are the same for all the independent variables. Figure 2.8: Homoscedasticity (Adapted 
from (Kumar, 2014)) shows the concept of homoscedasity. The points are aligned along the 




Figure 2.8: Homoscedasticity (Adapted from (Kumar, 2014)) 
For the viral load prediction, the attributes in question will not follow the assumptions listed 
above, and thus linear regression cannot be used for this research. 
 
2.4.5. K-Nearest Neighbor 
K-Nearest neighbor (KNN) algorithm is a non-parametric method that uses the full training set. 
It finds the k nearest neighbors to a query point and reports either their class by majority vote or 
the average of their resistance value (Shen, Yu, Harrison, & Weber, 2016).  
The neighbours are found by use of the distance measure, which can either be euclidean, 
manhattan or minkowski. The value of k is used to determine the number of neighbours which 
we aim to consider for the case, based on their distance. The algorithm stores all the cases that 
will be used for the testing, and will be accessed during runtime. Once the test case has been 
selected, the test case is compared with all the existing cases, calculating the distances between 
the test case and the cases. The distances obtained are then ranked, and the k smallest distances 
are selected as the neighbours (Sayad, 2017). To classify, the majority of the classes in the 
selected neighbors are chosen as the class of the test case. 
Figure 2.9 shows how the k-nearest neighbor algorithm. The point of interest is the red dot. The 
nearest neighbors to the dot are the two plus and the three minus. The 5 nearest neighbors in this 




Figure 2.9: Sample of K-Nearest Neighbor Classification (Adapted from (Statistica, 2017)) 
The distance could be determined by the Euclidean distance whose formula is shown in Equation 
2.3 where x is the instances, k is the number of features. We, therefore, sum the distance for each 
of the features, for the first instance xi and the test instance xj. This absolute value is obtained by 
squatting the difference.   
 
Equation 2.3: Euclidean Distance (Adapted from (Kataria & Singh, 2013)) 
 
In the study by Shen, et al., (2016), the k nearest neighbor algorithm was used. The k value was 
set to 6, with 210 dimension vectors for the training sample. The use of KNN algorithm makes 
the training of the model faster, but will utilize the complete training data in the prediction stage 
since the reporting of the result is done based on the training data. This makes the validation of 
the model very slow especially when working with very large number of cases. In this study, 
they were able to obtain R2 values ranging from 0.719 to 0.928 across 5 –folds. The closer the R2  
value is to 1, the better the prediction accuracy of the model.  
2.5. Conceptual Model 
The data to used in the system was obtained from the publicly available HIV patient databases. 
This data was cleaned for use in the training of the ANN system. This means that only specific 
data attributes were extracted, including the phenotype, the viral load (current), past viral loads, 
past and present CD4+ counts for the patient.  
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This data was then combined together based on the patient serial number and the specific dates in 
which the data for CD4+ counts and the viral load levels were measured. The ART history of the 
patient was also considered.  
The cleaned data was then categorized into two; one for training and one for testing. The drug 
resistance information for the specific ART regimen phenotypes was used together with the 
cleaned data to train the Artificial Neural Network, that first begins with arbitrary weights. 
Whenever a prediction is required, the patient information mimicking the one used in the 
training, is fed into the system and the system will pull drug resistance data from  the publicly 
available databases. The system then provides a prediction of the estimated viral load level for 
the patient over a given period of time. Figure 2.10 shows the conceptual working of the system. 
 




Chapter 3 : Research Methodology 
3.1. Introduction 
In this chapter, the research methodology used is outlined. The research design chosen, the 
population selected and the sampling method used will also be analyzed.  
3.2. Research Design 
Wanjugu (2015) defines research design as the structure that the research process follows in 
terms of collection, measurement, and analysis of data, with the aim of obtaining answers to the 
research questions. The author also states that one of the aims of research design is to combine 
relevance to the purpose of research with the economy in procedure.  
Research design can also be described as a general plan on how the various aspects of the 
research will be organized together in an orderly and meaningful manner, in order to ensure that 
the research problem is addressed adequately, by establishing how the data will be collected, 
measured and analyzed (Alick, 2016). 
This research is an applied research. This is because it aims to provide information that can be 
used and applied in an effort to help other people understand and control their environment. 
Applied research is more prescriptive in nature and seeks to offer potential solutions to problems 
(Center for Innovation in Research and Teaching, 2016).  
3.3. Model Development 
To develop the artificial neural network, the steps followed were as follows: 
i) Obtaining data 
ii) Pre-processing of data 
iii) Development of the model 
iv) Validation of the model 
3.3.1. Obtaining Data 
The data that was used in the building of the neural network regressor was obtained from the 
publicly available HIV Stanford database. This data was in form of XML files, which were 
downloaded directly as a zip file. The data consisted of 1518 individual XML files, and they 
contained the individual TCEs.  
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3.3.2. Data Pre-processing 
The data obtained for this study contained duplicates and gaps. The data had to be pre-processed. 
The TCE was first extracted from the XML file, and stored in a relational database. The 
extraction was done via PHP code that was developed. The duplicated were then eliminated and 
the complete data was then used to generate CSV files that could then be used for the training, 
testing and validation of the model. 
3.3.3. Development of the Model 
The model was developed using the sklearn library, which is an open-source Python library. The 
evaluation method was artificial neural network regressor with multiple layers. 
3.3.4. Validation of the Model 
The model generated was validated by use of the coefficient of determination (R2 ) measure and 
the mean square error (MSE). 
3.4. System Development Methodology 
The study utilized Data-driven Modelling (DDM) in the development of the system. This 
technique is useful in computational intelligence, machine learning and data mining. 
Computational intelligence includes neural networks (which this study relies on), fuzzy systems 
and evolutionary computing (Solomatine, See, & Abrahart, 2008). The Data-driven modelling 
methodology relies on analysis of the data available about a system, and particularly finding 
connections that exist between the input, internal and output variables. This modelling is done 
without any explicit knowledge of the physical behavior of the system. Figure 3.1 shows the 




Figure 3.1: Data-driven Modelling (Adapted from (Solomatine, See, & Abrahart, 2008)) 
3.4.1. Application of the Data-driven Modelling Methodology 
The input variables were obtained from an online source, and was categorized into training, test 
and validation data. The data was then processed by use of a machine learning algorithm; the 
artificial neural network. The data used in this model was representative of the behaviour found 
in the system. The model that was developed can be used to augment the operation of the 
Comprehensive Care Centers.  
The training data was used to train the model in a bid to have the model converge by minimizing 
the model error. The test data was used in performance evaluation of the model. This data was 
not used in to modify the model in any way, but to indicate the errors that may be present in the 
developed model. 
3.4.2. Techniques Used 
Some of the techniques used in this approach as stated by Solomatine, See and Abrahart (2008) 
are neural networks, fuzzy rule-based systems, genetic algorithms for model optimization, 
support vector machines, and chaos theory. This study used neural networks with 
backpropagation and multiple-layers.  
3.4.3. Model Testing and Deployment 
The system testing was undertaken by use of test data. The test data was set from the set of data 
obtained online. The level of efficiency obtained by the system was assessed from the test data 
and the validation data.  
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3.5. Research Quality 
Research Information Network, (2010) define quality research as research that has intelectual 
vigor, accurate recording and honest reporting of work, and integrity in the recognition of the 
work of others. This research followed quality standards by ensuring that all work that was used 
was properly cited and that the literature reviewed was obtained from reputable sources. The data 
collected and used was presented as is, except in instances of duplication of data entries and 
missing data, that would have affected the quality of model used. The results that were obtained 
were assessed based on R2  (coefficient and determination) and Mean Squared Error (MSE). 
The Mean Squared Error of prediction is the average squared difference between independent 
observations and the predictions from the model or equation . It incorporates both the variance of 
prediction and the square of the bias of the prediction. The equation used to compute this is 
shown in Equation 3.1. The n is the number of instances, Ŷpred(i) is the prediction of the 
observation (i) and Yi is the expected value. 
Equation 3.1: Formula for Computing Mean Squared Error (Adapted from Rawlings, Pantula, & 
Dickey, (1998) )  
 
 
Coefficient of determination (R2) is the proportion of the corrected sum of squares of Y that can 
be attributed from the information obtained from the independent variable (s). It usually ranges 
from zero to one and is the square of the product moment relation between Yi and Ŷpred(i) 
.Equation 3.2 shows the formula for computing coefficient of determination. In the formula, SSR 




Equation 3.2: Coefficient of Determination Formula (Adapted from PennState Eberly College of 
Science, (2017)) 
 
3.6. Ethical Considerations  
In the study, the researcher utilized publicly available online data, only after obtaining consent 
from the caretakers of the system. In addition, the researcher disclosed the use of the data as 
pertaining to the scope of the study and was subsequently granted access to the Sierra Web 
Service. Given that the data is based on patients’ treatment history, the researcher ensured that 
the data given only contained aliases that could not be linked to any particular patient, and that 
the data was only used for the purpose of this research. Attribution for the use of data was given 
to the owners of the data. The data collected by the researcher was used in the format without 




Chapter 4 : System Design and Architecture 
4.1. Introduction 
In this section, we will outline the design architecture of the developed HIV/AIDS viral load 
prediction system. This architecture will follow from the conceptual model shown in Figure 2.10. 
This section shall cover the interaction between the users and the developed system, the 
components of the developed system and the interaction between the various components of the 
developed system. This was modelled by use of class diagrams, use case diagrams, data flow 
diagrams and system sequence diagrams. 
4.2. Requirements Analysis 
The requirements that were gathered for this study can be categorized into three sections; the 
functional requirements, non-functional requirements and usability requirements. 
4.2.1. Functional Requirements 
i. The system should allow the user to input data as a CSV file, from the form or as an XML 
file. Any other formats of data input should be rejected. 
ii. The system should extract the viral load (RNA), CD4+ counts, the drug information and 
the duration from the uploaded data. 
iii. The system should predict the level of viral load (RNA) by use of the multilevel neural 
network. 
iv. The predicted viral load level should be valid based on the input given from the user. 
v. The system should provide a rating of the level based on the CDC guidelines. 
4.2.2. Usability Requirements 
The system is intended to be used at the hospital level. The main users will be the clinicians 
located at the hospital. The system should, therefore, be simple and straightforward to enhance 





4.2.3. Reliability Requirements 
i. The system should always be able to interface with the existing drug resistance 
database. 
ii. The system should be able to extract the treatment change episode from the input data 
either in CSV, XML or from the form. 
iii. The administrator should be able to correctly restore the system to a functioning state in 
the event of a failure. 
4.2.4. Supportability Requirements 
The system should be accessible as a web application. The system should be accessible across all 
the major web browsers, and across all the major desktop platforms.  
4.3. System Architecture 
The architecture for the system is as shown in Figure 4.1. The main input to the system will be 
the treatment change episode (TCE) of the patient. This is data showing the previous, baseline 
and future levels of RNA, mutations of the virus across time and the regimens used during the 
period. These parameters will be standardized before being fed into the neural network. The data 
is split into the training and test data, which will be used in the training phase. Once the training 
has been done, the subsequent data input will utilize the trained model in the prediction of the 
viral load level. The viral load level given as output shall then be compared to the set CDC 




Figure 4.1: System Architecture 
4.4. Use Case Diagram 
The actors in this system are the administrator, the clinician, and the sierra drug resistance 
database. The administrator performs data pre-processing and model training. The data pre-
processing includes the standardization of the data to prepare it for use in the training of the 
model. It also includes feature extraction where the features with the most information gain are 
selected. In addition to this, the percentage of drug resistance is obtained from the sierra system 
(drug resistance database) which is also standardized. Under model training, the administrator 
utilizes the data obtained from the data pre-processing stage to train the neural network. The 
sierra system is used to perform the computation of the drug resistance percentage, which is used 




The users who use the system have been identified and depicted in Figure 4.2. The clinician 
interacts with the system by providing the data that will be used in the prediction. S/he will be 
performing prediction of the viral load level. This step utilizes the functionality of the model that 
has been saved from the model training, and the resistance percentage obtained from the sierra 
system. This would, thus, output the predicted viral load level and the recommendation. Table 










Table 4.1: Data Pre-processing, Standardization and Feature Extraction 
Use Case: Data Pre-processing, Standardization, and Feature Extraction 
Primary Actors: Administrator 
Precondition: Feature Selection System Available, Standardization Function 
Post-condition: Treatment Change Episode obtained should have all required features 
Main Success Scenarios 
Actor Intention System Responsibility 
1. Administrator inputs dataset  
2. Administrator selects feature 
extraction parameters 
 
 3. System runs feature extraction  












Table 4.2: Model Training and Testing 
Use Case: Model Training and Testing 
Primary Actors: Administrator 
Precondition: Pre-processed Treatment Change Episode 
Post-condition: A multilevel neural network model for viral load level prediction  
Main Success Scenarios 
Actor Intention System Responsibility 
1. Administrator selects the neural 
network features 
 
2. Administrator selects the number of 
epochs to run 
 
3. Administrator enters the target 
output for the data 
 
 4. System trains the model based on the 
number of epochs 
 5. System generates neural network model 
and saves it as pickle file 
 6. System tests generated model using test 
data 







Table 4.3: Obtaining the Predicted Viral Load Level 
Use Case: Get Viral Load Level 
Primary Actors: Clinician 
Precondition: A multilevel neural network model for viral load level prediction, Valid Treatment 
Change Episode (TCE), Drug Resistance Percentage 
Post-condition: Predicted Viral Load Level and Recommendation  
Main Success Scenarios 
Actor Intention System Responsibility 
1. Clinician Enters the TCE  
 2. Perform Prediction from data 
 3. Return predicted level, recommendation, and 
accuracy 
4. Clinician views predicted level, 
recommendation, and accuracy 
 
  
4.5. System Sequence Diagram 
Figure 4.3 shows the sequence diagram for the system. The Clinician inserts data, which is 
basically a treatment change episode either in a CSV, XML or form. The uploaded data 
undergoes feature extraction to get the features with the most information gain. This data is split 
into the test and training cases and fed into the multilevel neural network to create the model. 
The system then performs the prediction for the level and then compares the results to the 
guidelines from CDC. Once this information has been obtained, the result is given back to the 




Figure 4.3: System Sequence Diagram 
4.6. Flow Chart 
The process flow for the training of the model is as shown in Figure 4.4. The treatment change 
episode (TCE) is entered and data pre-processing is undertaken on it. The data in it is tested with 
a generated model based on the number of epochs. If the model is not considered optimal (lack 
of convergence) then it checks if the stopping condition has been met. This stopping condition is 
basically the number of epochs that has to be run while training the system. By this time, the 
model has not been saved. If the specified number of epochs has been met, then the system stops.  
If the specified number of epochs has not been reached, a new model is generated by readjusting 
the weights and training the model. The trained model is then reevaluated for its optimality, and 
there is convergence, the model is saved as a pickle file. The system then checks to see if the 
stopping condition has been met. This process is repeated until the stopping condition is met. 




Figure 4.4: Flow Chart for the System 
4.7. Database Schema 
The system has a database as defined in Figure 4.5. The database contains a total of 11 
normalized tables. The types table contains the duration within which the treatment, viral load 
(RNA) or CD4+ counts were taken, and is either Past, Baseline (beginning of testing) and 








Chapter 5 : Implementation and Testing 
5.1. Introduction 
The prototype was developed through the use of neural network multi-layer perceptron regressor. 
The model was implemented as a standalone system, consisting of a PHP web application, a 
python backend API and a neural network developed in python. The data used in the system was 
stored in MySQL database. 
The data was entered through the web interface, and was saved in the database. This data 
consists of fasta files, the nucleotide sequences or the treatment profile of the new patient. The 
nucleotide sequence and the fasta file was then used to get the drug specific resistance level from 
the system. The treatment profile (TCE) was used in the prediction of their viral load level. The 
multi-layer neural network regressor, trained by use of backpropagation, was used in the 
prediction of the viral load levels for the HIV/AIDS positive patient. The neural network was 
trained by use of training set of data, and the result of the prediction are displayed to the user on 
the web interface with the recommendation.  
5.2. Model Components 
5.2.1. System Components 
The web system developed contained two sections of data input. The first section was the drug 
resistance interface which is a public interface that allows anyone with the knowledge of the 
website to easily obtain resistance reports of the HIV/AIDS regimens. It contains two inputs 
sections; the nucleotide and the fasta file. The fasta file is a text file that contains the nucleotide 
sequences in a list, separated by a character, in this case, it is ‘> ’. This interface is shown in 
Figure 5.1 below. The output of the analysis is displayed in a pop-up interface.  
The private section can be accessed by logging into the system with valid credentials, either as 
an administrator or as a clinician. The administrator is able to undertake administrative tasks 
such as addition, editing and deletion of users. In addition, s/he is able to compute the drug 
resistance for a set of inputs in the system based on the nucleotide sequence already existing. The 
clinician is able to enter a number of parameters, which includes the past CD4+ counts, the past 
viral load levels, the drug regimens that the patient has been on in the past, and the nucleotide 
sequence that was there in the past. The clinician is also be able to add the baseline (current 
during prediction) levels of the viral load, and the CD4+ counts, and the nucleotide if present. 
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The baseline year is the current year if none is entered/ selected, and the unit of time measure 
used (i.e. either weeks, days, months) has to be selected. The duration under consideration for 
prediction has to be selected too. If none is selected, the default prediction period of 8 weeks is 










Figure 5.2: Add New Treatment Change Profile Interface 
5.2.2. Neural Network Components 
The multilevel perceptron neural network includes several components as listed below 
5.2.2.1 Input Layer 
The input layer is the first layer in the neural network. It contains neurons that correspond to the 
number of attributes that are used by the neural network to predict the values. A bias node is also 
included in this layer to ensure that the neural network will be able to fit the data. The model 
used consists of 8 nodes. The inputs to the system are the past CD4+ count, the baseline CD4+ 
count, the past viral load log level, the baseline viral load log level, past average drug resistance, 
the baseline average drug resistance, the duration between the past treatment start date and the 




5.2.2.2 Hidden Layer 
The hidden layer is a series of neural network layers of nodes which serve to enhance the 
prediction accuracy of the network. This is done by having a series of nodes with activation 
functions. These neurons would also serve to prevent overfitting of data to the model, and under 
fitting of data to the model. Karsoliya, (2012) stipulates that the number of hidden layers should 
be less than twice the number of neurons in the input layer. This prevents underfitting and 
overfitting. Thus the formula chosen for this model was 2n-1 . The model developed used 15 
hidden layers, given that it is a prediction system with a sizeable number of variables.  
5.2.2.3 Output Layer 
This is the final layer of the neural network, and it serves to produce the output from the neural 
network. The model selected was a neural network regressor which had multiple output values 
from one output node. 
5.3. Model Implementation 
5.3.1. Data Input 
The data to be input is in form of either XML, CSV, fasta file or text. The clinician uploads the 
file on the system, and runs an analysis of the same. The fasta file contains a list of nucleotide 
sequences as shown in Appendix A. The XML file used needs to have at least one past viral load 
(RNA) level count and its log, the past CD4+ count, the baseline (current) RNA and CD4+ 
counts, the patient alias, the unit of measure and the regimens used in the management of the 
virus. A sample of the XML can be seen in Appendix B.  
The data is extracted from the various input fields and inserted into the MySQL database based 
on the patient alias as the linking attribute. If the logarithmic value for the viral load level is not 
entered, the system computes its logarithmic equivalent using Equation 5.1. This value is stored 
in the database.  




5.3.2. Drug Resistance Computation 
Each of the regimen that the HIV positive patient is on consists of a cocktail of a number of 
drugs. These drugs have a specified resistance that can be estimated. The Stanford HIV drug 
resistance database is able to provide the predicted resistance values. The HIV/AIDS viral load 
prediction system utilizes this functionality to obtain the resistance. This is done through the use 
of the Sierra web service. The resistance is based on the specific nucleotide and the 
approximated drug resistance as identified from the mutations in the nucleotide.  The predicted 
drug resistance contains a summary of all regimen drugs with their associated resistance. 
However, a patient may not be on all the drugs and as such the resistance would be a function of 
the average resistance based on the number of drugs. The function is defined in Equation 5.2.  
Equation 5.2: Determining Drug Resistance for a Patient 
 
5.3.3. Scaling Data 
The data obtained from the clinician needs to be fed into the neural network during the training, 
testing, validation and model use phases. This data needs to fit within the range [0, 1] for it to be 
valid in its use. Given the variance of the viral load logload and the actual values, the need for 
normalizing the data is apparent.  This is done based on the formula on Equation 5.3. The 
standard scaler removes the mean of the data and scaled the data to unit variance. x is the 
original vector, µ is the mean of the vectors, and δ is the standard deviation. This is useful as it 
helps improve the prediction performance of the model.  




The tables Table 5.1 and Table 5.2 show sample data that was used in the training of the system. 
The variation between the values for the CD4+ count is very large, but once standardized, this 
variation decreases largely.  
Table 5.1: Table Showing Unstandardized Data 







Table 5.2: Table Showing Standardized Data 






5.3.4. Software Flow 
A web application was developed that allowed the clinician to add the treatment change episode 
for a particular patient. The clinician has to log in first, and add the treatment profile (TCE) to 
the system and save it. The TCE contains information on the past treatment, the present 
treatment, viral load levels for the past and present, the CD4+ counts for the past and the present, 
the nucleotide sequence(s) and the duration for which the prediction is expected to cover. The 
default duration is 8 weeks.  
Once the profile has been saved, the clinician is taken to another interface from where they can 
perform the prediction of the viral load. Here the system queries for the drug resistance from the 
Stanford HIV database through the Sierra web system via an API call.  
44 
 
The resistance to the specific drugs is compared with the drugs that the user is on and the average 
stored. The resistance is a predicted value hence the average is taken to simplify the viral load 
prediction process and ensure that the number of attributes remains constant. The clinician is 
then given an interface with the final predicted value for the viral load level, and the 
recommended course of action. The environment used in the development of the system are as 
follows: 
i. Windows 10 Home Edition 
ii. Sublime Text 3  
iii. Python 2.7  
iv. PHP 5.6 
v. Numpy version 1.11.3 
vi. Scikit learn version 0.18.1 
vii. Jetbrains Pycharm Student Edition  
5.4. Model Architecture 
The model that has been developed in this research is as depicted in Figure 5.3. The data once 
uploaded will be saved into a local database. The data is then completed by obtaining the 
resistance for each patient based on their nucleotide sequence and the drug resistance. This data 
is then used in the prediction. The data is preprocessed to extract some specific attributes and 
then scaled to fit within a given range. This is done by use of the standard scaler function. The 
scaled data is then passed through the neural network regression model which outputs a value. 




Figure 5.3: Model Architecture 
5.5. Model Validation and Testing 
The University of Edinburgh, (2017) defines model validation as the task of showing that the 
model created is representative of the actual system to a reasonable degree. This means that the 
model produces results similar to what the actual system would, with enough confidence to allow 
analysis to be performed on the results produced.  
NIST/SEMATECH, (2017) asserts that model validation is one of the most important aspects of 
building a model. This importance is underscored by the assertion that this is also one of the 
most overlooked aspects in the entire model generation process. NIST/SEMATECH, (2017) 
mentions the use of the R2 statistic as a commonly used measure in the analysis of models. This 
performance measure was used in the analysis of the developed model as is discussed in chapter 
6. The functional requirements, usability requirements, and supportability requirements are what 
were used to look at the validity of the developed model. 
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5.5.1. Functional Requirements 
Table 5.3 shows the functional requirements for the system. The elements assessed were valid 
predictions, extraction of data and allowing multiple input forms. 
Table 5.3: Functional Requirements 
Requirements Priority Result 
Allow user to input data as CSV, 
form or XML file 
High The system allowed the data to be input 
from the specified sources only, and a 
sample CSV file was provided in order to 
ensure the data was properly captured. A 
valid XML format was also provided.  
System should be able to extract 
the data from the input sources 
High The system was able to get the various 
data from the specified sources and store 
the value 
Predicted viral load level should 
be valid based on the user input 
High The system was able to predict the viral 
load levels from the given user input to a 
given degree of confidence 
The system should provide a 
rating based on the Centers for 
Disease Control (CDC) 
guidelines 
 
Medium The system compared the predicted viral 
load levels to the guidelines given by the 






5.5.2. Usability Requirements 
Table 5.4 shows the usability requirements for the system. The simplicity of use, access to the 
system and speed of use of the system were analyzed. 
Table 5.4: Usability Requirements 
Requirements Priority Result 
Simplicity of Use High The system had few interfaces which 
were straightforward to ensure that the 
users were using the system optimally 
Access to the system 
 
Medium The system contained some aspects that 
could be accessed without the need to log 
in. This would allow the users to perform 
routine tasks with ease.  
The system was also web based thus can 
be easily scaled and accessed widely.  
The system also allowed the user to 
perform multiple analysis at a time, 
therefore reducing the time the user 
while using the system 
Speed of the system 
 
High The speed of the system was wanting but 
could still be used effectively. This was 
as a result of the request to an external 
API for drug resistance. The performance 








5.5.3. Reliability Requirements 
Table 5.5 shows the reliability requirements for the system. The ability of the system to interface 
with other systems, restoration of the system and extraction of the TCE were assessed. 
Table 5.5: Reliability Requirements 
Requirements Priority Result 
Ability to interface with the drug 
resistance database 
High The system is able to interface 
appropriately with the drug resistance 
database via the Sierra web system API 
Extracting the Treatment 
Change episode from input data 
High The system was able to successfully 
extract the treatment change episode 
from the input methods that followed the 
correct procedure 
Administrator restoring system 
to functioning state in case of 
error 
Medium The codebase and database was routinely 
backed up on Github and Firebase 





5.5.4. Supportability Requirements 
Table 5.6 shows the supportability requirements for the system.  The ability of the system to run 
across multiple browsers and to run on multiple desktop platforms were assessed.  
Table 5.6: Supportability Requirements 
Requirements Priority Result 
Accessibility across all browsers High The system was accessible across major 
browsers; Google Chrome, Safari, 
Mozilla Firefox and Microsoft Edge. 
This fact will be disclosed when 
deploying the system and will form part 
of the system requirements 
 
Accessibility across all desktop 
platforms 
Medium The system can be deployed on Windows 
and Linux systems. The codebase was 
developed to cater for the two major 




Chapter 6 : Discussion 
6.1. Introduction 
The HIV/AIDS viral load system was implemented by use of data from the online HIV Stanford 
Database. This data comprised of the patient’s treatment change episode (TCE), which contains 
the drugs used in the past, the drugs currently being used, the CD4+ counts and viral load levels 
for the patient before the change of regimen, and during the new treatment. The TCE also 
contained the nucleotide sequences for the virus, which was used in the determination of the drug 
resistance levels for the medication the patient was on. This drug resistance was obtained from 
the Sierra Service. The models performance was evaluated based on the mean square error 
(MSE) and the coefficient of determination (R2). The model was developed by use of a 
backpropagation artificial neural network with multiple-layers. The use of neural networks 
provided a faster way of performing the predictions for the HIV/AIDS viral load levels.  
6.2. Model Validation 
The prediction accuracy for the developed model was determined by the coefficient of 
determination and the mean square error. A cross validation of 10 folds was used to validate the 
model. The prediction accuracy of the model was set to 93.76%. This was done on a data set of 
374 individual TCEs. The TCEs were selected from a group of 1518 TCEs, and involved 
removing any duplicates and TCEs with incomplete data. The mean square error for the trained 
model was 0.0323. A lower MSE denotes a better model that has been trained whereas a R2 
value closer to 1 denotes a better model that has been developed. The optimal learning rate for 




6.3. Model Implementation Outputs 
6.3.1. Training Outputs 
The training outputs from the model trained were as captured in Table 6.1 This data was 
obtained after 298 iterations due to convergence of the model. The model had a mean square 
error (MSE) of 0.02587 with a learning rate of 0.0005. The coefficient of determination of 
0.97412.  
Table 6.1: Sample Expected Output and Predictions on Training 
Expected Output Predicted Output Error 
-0.843767364 -0.816364 -0.027403364 
-0.137077927 -0.207077 0.069999073 
1.197779898 1.393897 -0.196117102 
1.11925885 1.291918 -0.17265915 
0.962216753 1.061611 -0.099394247 
-0.843767364 -0.805855 -0.037912364 
-0.843767364 -0.804018 -0.039749364 
-0.686725267 -0.638511 -0.048214267 
-0.686725267 -0.71183 0.025104733 
0.412569413 0.345061 0.067508413 
Mean Square Error (MSE) 0.025876  
Coefficient of Determination (R
2





6.3.2. Testing Outputs 
The testing outputs from the model trained were as captured in  
Table 6.2.Table 6.1. This data was obtained after 620 iterations until convergence of the model. 
The model had a mean square error (MSE) of 0.087833 with a learning rate of 0.0005. The 
coefficient of determination of 0.912167. 
Table 6.2: Sample Expected Outputs and Predicted Outputs on Testing 
Expected Output Predicted Output Error 
-0.84031933 -0.566701 -0.27362 
-0.685787445 -0.577036 -0.10875 
1.091329229 0.970283 0.121046 
0.009606036 -0.326198 0.335804 
0.318669805 0.082967 0.235703 
0.395935748 0.180087 0.215849 
-0.84031933 -0.741415 -0.0989 
0.009606036 0.00037 0.009236 
-0.685787445 -0.691041 0.005254 
-0.685787445 -0.508442 -0.17735 
Mean Squared Error (MSE) 0.087833  
Coefficient of Determination (R
2





6.3.3. Validation Outputs 
The validation outputs from the model trained were as captured in Table 6.3.This data was 
obtained after 620 iterations until convergence of the model. The model had a mean square error 
(MSE) of 0.062349 with a learning rate of 0.0005. The coefficient of determination of 0.937650. 
Table 6.3: Sample Expected Outputs and Predicted Outputs on Validation 
Expected Output Predicted Output Error 
-0.845635997 -0.768517 -0.077118997 
-0.683381765 -0.670127 -0.013254765 
-0.115491953 -0.496783 0.381291047 
-0.845635997 -0.839473 -0.006162997 
-0.683381765 -0.642442 -0.040939765 
-0.358873301 -0.325721 -0.033152301 
-0.683381765 -0.682973 -0.000408765 
1.993813061 1.615 0.378813061 
-0.358873301 -0.599878 0.241004699 
1.101414786 1.131859 -0.030444214 
Mean Squared Error (MSE) 0.062349  





6.4. Contributions to Research 
The model developed provided a solution to estimating viral load levels in HIV-positive patients, 
especially in limited resource settings. This model helps the clinician estimate the likelihood of a 
patient’s prescribed treatment not being effective, and thus can institute further monitoring on the 
patient. This also reduces the need for the continual measurement of viral load of HIV-patients, 
especially in limited resource settings. 
6.5. Challenges 
Availability of quality data was a challenge during the study. The data was obtained from 
secondary sources, and contained gaps and duplicates. This reduced the available training data 




Chapter 7 : Conclusions and Recommendations 
7.1. Conclusions 
The main objective of this research was to develop a HIV/AIDS viral load prediction system that 
utilizes the artificial neural network algorithm. This objective was split into five major objectives 
in order to adequately achieve the main objective. These major objectives are as follow: 
i) To investigate the factors influencing the HIV/AIDS progression in human beings 
ii) To analyze the methods used in the measurement of HIV/AIDS progression 
iii) To review the existing prediction algorithms and models used in the prediction of 
HIV/AIDS progression 
The first three objectives were met by reviewing existing literature. These algorithms helped the 
researcher to identify the factors affecting the progression, and enabled the researcher to 
understand which attributes contribute to the final viral load of the HIV-positive patient. This 
was covered in chapter 2.  
iv) To develop an HIV/AIDS viral load prediction system 
The system was developed using secondary data. Data-driven modelling was used, and this is 
discussed in chapter 3. The design for the system included the use case, flow chart and database 
schema. These designs were used to model how the system components interact, and therefore 
guide the development of the system. This objective was met and is covered in chapter 4 and 
chapter 5. The tools used in the design of the system included Microsoft Word. 
v) To test the functionality of the developed HIV/AIDS viral load prediction system 
Evaluation of the functionality of the developed system was done by validating the outputs 
generated from the developed system against the expected output. The ease of use of the system 






Wasti, et al., (2012) and Beer, et al., (2012) identified that a high level of patient adherence to the 
prescribed antiretroviral therapy (ART) regimen. This means that the viralogical success of the 
treatment has to fall within the prescribed 95% that Wasti, et al., (2012) suggested. This implies 
that the patient would require to be strictly following the regimen as indicated in order to have an 
optimal viral suppression to prevent superinfection or transmission of the virus. 
This study has also shown that the use of multi-layer back-propagated artificial neural networks 
in prediction of a HIV-positive patient’s viral load level is possible. The study showed the 
relatively high accuracy levels that were obtained from the developed model, with the data pre-
processed first and applied to the neural network model. The pre-processing ensured that the 
model was able to perform with high accuracy and eliminated bias.  
The model created was able to produce predictions that had high accuracy and low errors as 
indicated by the findings in the study. This illustrates the ability of neural networks to be used in 
dispensing centers and comprehensive care centers to perform prediction of HIV/AIDS viral load 
levels. The study findings also pointed out the need to have more data attributes collected from 
the patients in order to better improve the model generated. This would help in the monitoring 
and follow-up of the patients’ to ensure appropriate care is given. 
7.2. Recommendations 
From the results obtained, the following recommendations can be made: 
i. The degree of adherence to the prescribed ART regimen by the patient can be utilized in 
the model to improve the outputs of the prediction 
ii. The model can also be trained with data from known sources so as to evaluate the 
effectivity based on location 
iii. More data to be collected in order to further improve the model’s prediction performance 
7.3. Suggestions for Future Research 
More research could be done on how to estimate the patient’s adherence to the prescribed 
regimen by use of their lifestyle. This could provide a basis for computing the adherence 
percentage which could be used as an input to the developed model. The developed system 
should also be interlinked with the currently existing systems to provide seamless integration of 
the systems. This will eliminate the need to have to manually transfer data, and ultimately 
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eliminate the errors attributable to human intervention. The data could be used to train the model 
periodically thus resulting to improved prediction accuracy.  
Other types of Artificial Neural Networks such as associative neural networks can be used to 
develop the model. This can ultimately lead to the determination of the most optimal neural 
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Appendix C: Sample XML 
Part of the Sample XML file. Note: The XML file is very long hence the cropping. 
 
 
